LIVER INT 润色咨询

LIVER INTERNATIONAL

出版年份：2003 年文章数：2252 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：4.3% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向： 肝病 ; 临床 <br>经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向：细胞生物<br>经验分享：想问一下各位大佬，这个期刊接受纯机制研究吗？没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享：跟楼上一个哥们挺像，综述投了一个半月 ，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？ 毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：目前影响因子8.76分了，非常不错，希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多，如何选择合适的期刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：投稿3天直接拒稿，效率高，投稿系统友好，但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-04-23 Yi wen

    审稿速度:3.0 | 投稿命中率:25.0
    偏重的研究方向： 肝病 ; 临床
    经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向： 肝病 ; 临床 <br>经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向：细胞生物<br>经验分享：想问一下各位大佬，这个期刊接受纯机制研究吗？没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享：跟楼上一个哥们挺像，综述投了一个半月 ，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？ 毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：目前影响因子8.76分了，非常不错，希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多，如何选择合适的期刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：投稿3天直接拒稿，效率高，投稿系统友好，但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2022-11-16 ms6000001546419962

    偏重的研究方向：细胞生物
    经验分享：想问一下各位大佬，这个期刊接受纯机制研究吗？没有临床数据

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向： 肝病 ; 临床 <br>经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向：细胞生物<br>经验分享：想问一下各位大佬，这个期刊接受纯机制研究吗？没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享：跟楼上一个哥们挺像，综述投了一个半月 ，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？ 毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：目前影响因子8.76分了，非常不错，希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多，如何选择合适的期刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：投稿3天直接拒稿，效率高，投稿系统友好，但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2020-09-07 ms4000000689346681

    审稿速度:2.0
    经验分享：跟楼上一个哥们挺像，综述投了一个半月 ，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？ 毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。

    2

    展开2条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向： 肝病 ; 临床 <br>经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向：细胞生物<br>经验分享：想问一下各位大佬，这个期刊接受纯机制研究吗？没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享：跟楼上一个哥们挺像，综述投了一个半月 ，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？ 毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：目前影响因子8.76分了，非常不错，希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多，如何选择合适的期刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：投稿3天直接拒稿，效率高，投稿系统友好，但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-10-15 YJJJJJ

    9-7 提交
    10-10 拒稿
    第一个审稿人完全否定
    第二个审稿人列出了大量的建议
    副主编也给出了一条建议
    总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投.

    6

    展开6条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向： 肝病 ; 临床 <br>经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向：细胞生物<br>经验分享：想问一下各位大佬，这个期刊接受纯机制研究吗？没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享：跟楼上一个哥们挺像，综述投了一个半月 ，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？ 毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：目前影响因子8.76分了，非常不错，希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多，如何选择合适的期刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：投稿3天直接拒稿，效率高，投稿系统友好，但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2022-06-29 Dr.？？？

    审稿速度:6.0 | 投稿命中率:25.0
    经验分享：目前影响因子8.76分了，非常不错，希望明年到十分

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向： 肝病 ; 临床 <br>经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向：细胞生物<br>经验分享：想问一下各位大佬，这个期刊接受纯机制研究吗？没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享：跟楼上一个哥们挺像，综述投了一个半月 ，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？ 毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：目前影响因子8.76分了，非常不错，希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多，如何选择合适的期刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：投稿3天直接拒稿，效率高，投稿系统友好，但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2022-05-21 peach_adore

    mark

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向： 肝病 ; 临床 <br>经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向：细胞生物<br>经验分享：想问一下各位大佬，这个期刊接受纯机制研究吗？没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享：跟楼上一个哥们挺像，综述投了一个半月 ，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？ 毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：目前影响因子8.76分了，非常不错，希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多，如何选择合适的期刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：投稿3天直接拒稿，效率高，投稿系统友好，但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2022-02-11 zhiyinghe2012

    ，

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向： 肝病 ; 临床 <br>经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向：细胞生物<br>经验分享：想问一下各位大佬，这个期刊接受纯机制研究吗？没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享：跟楼上一个哥们挺像，综述投了一个半月 ，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？ 毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：目前影响因子8.76分了，非常不错，希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多，如何选择合适的期刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：投稿3天直接拒稿，效率高，投稿系统友好，但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-12-29 MS68862005

    选刊的流程是什么？

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向： 肝病 ; 临床 <br>经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向：细胞生物<br>经验分享：想问一下各位大佬，这个期刊接受纯机制研究吗？没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享：跟楼上一个哥们挺像，综述投了一个半月 ，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？ 毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：目前影响因子8.76分了，非常不错，希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多，如何选择合适的期刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：投稿3天直接拒稿，效率高，投稿系统友好，但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-12-28 小动量

    期刊分类很多，如何选择合适的期刊？

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=959788, encodeId=fcc1959e8873, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向： 肝病 ; 临床 <br>经验分享：很严谨的期刊，已投中一篇完整的病例报告，审稿人的专业建议非常详细，经过2次仔细修改，杂志接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/12/f81c064046dd439aeb8df3ca4627b280.jpg, createdBy=75e25305266, createdName=Yi wen, createdTime=Fri Apr 23 15:30:33 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向：细胞生物<br>经验分享：想问一下各位大佬，这个期刊接受纯机制研究吗？没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享：跟楼上一个哥们挺像，综述投了一个半月 ，拒稿啦，附带了2个审稿人的修改意见，也是夸赞了写的不错，但就是存在几个问题，我不懂这是委婉的表达呢？还是我还有机会？ 毕竟没有被指出语言方面的问题，就是需要更加丰富一下我的内容，于是我在师姐的鼓励下，准备改一改重新再投回去了，后续结果是什么就一切随缘吧，要是我成功上岸，再来跟大家分享经验，指明大家前行之路。。要是我又一次被拒了，我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享：目前影响因子8.76分了，非常不错，希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.？？？, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多，如何选择合适的期刊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：投稿3天直接拒稿，效率高，投稿系统友好，但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-04-03 ms5000000232033363

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享：投稿3天直接拒稿，效率高，投稿系统友好，但不容易中

    0

共112条页码: 2/12页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分